MRM Health NV is a biopharmaceutical company focused on the discovery and development of innovative therapeutics based on the human microbiome.
#MRMHealth
📢 #VIBspinoff@HealthMrm announces positive Phase 2 results in mild-to-moderate #UlcerativeColitis. The trial demonstrated an excellent safety profile and initial efficacy on disease activity evidenced in clinically relevant parameters. 👇 https://t.co/oeoMFx0eTc
Another milestone for MRM Health: Today we announced positive results from our Phase 2a study with MH002 in mild-to-moderate Ulcerative Colitis! Discover more: https://t.co/zcav9Okdty
#MH002#UlcerativeColitis#microbiome#therapeutics
Proud to be one of the 25 innovative & disruptive companies selected to pitch during the Health Tech Innovation days in Paris (Oct 13-14, 2022)!
#HTID#Microbiome#IBD#innovation#biotech
Our second clinical trial has been approved by the Belgian regulators (FAMHP)!! This phase 2 study in Pouchitis is a multi-center, open label trial which will enrol up to 20 acute Pouchitis patients. Read about it here: https://t.co/a9iFaNKC8h
#microbiome#microbiota#pouchitis
Read about some of our exciting liver disease work here at MRM Health. Results from a collaboration with the Liver Unit, Department of Internal Medicine, Hospital Universitari Vall d’Hebron have just been published.
https://t.co/GykzJc7RJe
#microbiome#nafld#gutliveraxis
Our CEO, Sam Possemiers, and our CSO, Nigel Horscroft, will be presenting at the 6th #Microbiome Movement Drug Development Summit next week. The presentations will cover our programs in #IBD, #NAFLD/#NASH, Type 2 #Diabetes and #Parkinson’s Disease
https://t.co/Cs1nh7WBsm
We're very proud to be recognized as the Best emerging Clinical-stage Biotech Company – 2022 by Corporate Vision Magazine! Check out our pipeline at https://t.co/lp75vZFpWj to see our plans for the future.
@Corp_Vision#microbiome#Biotech#therapeutics
We are very proud to announce that the first patient has been dosed in a phase 1b/2a trial in Ulcerative Colitis. MH002 is our first clinical candidate resulting from our proprietary CORAL™ platform technology. #biotechnology#ulcerativecolitis#clinicaltrial#microbiome
Want to learn more about our Phase 1b/2a #clinicaltrial in #UlcerativeColitis? If you're at the 9th #Microbiome R&D and Business Collaboration Forum in Rotterdam on Tuesday 26th October then come along to hear #MRMHealth CEO and co-founder Sam Possemiers tell all